{"product_id":"mec-20th-annual-miami-cancer-meeting-2024","title":"MEC 20th Annual Miami Cancer Meeting 2024","description":"\u003ch3\u003eMEC 20th Annual Miami Cancer Meeting 2024\u003c\/h3\u003e\n\u003cul class=\"eo-event-meta\"\u003e\n\u003cli\u003e\n\u003cstrong\u003eStart:\u003c\/strong\u003e 19 January 2024\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eEnd:\u003c\/strong\u003e 21 January 2024\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eVenue:\u003c\/strong\u003e The Westin Tampa Waterside Hotel\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cstrong\u003eConference Description\u003c\/strong\u003e\u003cbr\u003e\u003cbr\u003eMEC 20th Annual Miami Cancer Meeting 2024 The areas of focus for this conference will include the current standards of care in the treatment of the aforementioned malignancies and new developments in theSe areas of Cancer care. There Will be much emphasis on molecular diagnosis and individualization of cancer therapy based on molecular profiles.\u003cbr\u003e\u003cbr\u003eThere will be reviews of new chemOtherapeutic, antiangiogenic, and immUnotherapeutic agents. Topics in solid tumors and hematological malignancies will be reviewed and will include tepics in breast cancer, lung cancer, gastrointestinal (GI) malignancies, gynecologic malignancies, genitourinary (GU) cancers head and neck cancers, melanoma, and hematological malignancies such as multiple myeloma, CLL and non-Hodgkin’s-lymphoma. There will also be a special session devoted to toxicity profiles, sUpportive care, and challenges in cancer therapy.\u003cbr\u003e\u003cbr\u003ePresentations from the latest national (AACR, ASCO, SABC, and ASH) and international forums (ESMO and WCLC) meetings Will be discussed and guidelines of cancer care using a team approach will be emphasized. The participants in the conference will have the opportunity not only to learn, review,- and understand the state-of-the-art‘ management in cancer care using a team approach but also engage in personal interaction with our panel of exports in these subjects during the questions and answers sessions.\u003cbr\u003e\u003cbr\u003eThis 3-day conference is designed for medical oncologists, hematologists, radiation oncologists, surgical oncologists, physician associates (PA), advanced registered nurse practitioners (ARNP), oncology nurses, registered pharmacists, pharmacy technicians, and radiation therapists. General practitioners will have the benefit of reviewing standard care and new developments in cancer management. Residents in training and fellows from these, specialties are encouraged to attend.\u003cbr\u003e\u003cbr\u003e\u003cstrong\u003e+ Include: 26 videos + 1 pdf, size: 3.31 GB\u003c\/strong\u003e\u003cbr\u003e\u003cbr\u003e \u003cbr\u003e\u003cbr\u003e\u003cstrong\u003e+ Topics:\u003c\/strong\u003e\n\u003cbr\u003e\u003cul\u003e\n\u003cli\u003eAcute Myeloid Leukemia.mp4\u003c\/li\u003e\n\u003cli\u003eB-Cell NHL (Aggressive) – Relapsed (CAR T versus Bispecifics).mp4\u003c\/li\u003e\n\u003cli\u003eB-Cell NHL (Low-Grades).mp4\u003c\/li\u003e\n\u003cli\u003eBi-Specific Inhibitor \u0026amp; ADC in Lung Cancer.mp4\u003c\/li\u003e\n\u003cli\u003eChallenges in Targeting Head and Neck Squamous Cell Carcinoma.mp4\u003c\/li\u003e\n\u003cli\u003eChronic Lymphocytic Leukemia.mp4\u003c\/li\u003e\n\u003cli\u003eControversies in Breast Cancer Use of ctDNA to Tailor Systemic Adjuvant \u0026amp; Post-neoadjuvant Therapies (Part 1).mp4\u003c\/li\u003e\n\u003cli\u003eControversies in Breast Cancer Use of ctDNA to Tailor Systemic Adjuvant \u0026amp; Post-neoadjuvant Therapies (Part 2).mp4\u003c\/li\u003e\n\u003cli\u003eControversies in Lung Cancer Neoadjuvant vs Adjuvant IO in Early Stage NSCLC.mp4\u003c\/li\u003e\n\u003cli\u003eEndocrine Therapy for Early -and Late- Stages Breast Cancer Therapeutic Updates.mp4\u003c\/li\u003e\n\u003cli\u003eFlyer.pdf\u003c\/li\u003e\n\u003cli\u003eFront Line Targeted Therapy in NSCLC Tyrosine Kinase Inhibitors.mp4\u003c\/li\u003e\n\u003cli\u003eHER-2 Disease Amplification, Overexpression, Mutation in Breast Cancer.mp4\u003c\/li\u003e\n\u003cli\u003eHow to Handle Myelotoxicity from Chemotherapy in 2024 From Colony-Stimulating Factors (CSF) to Agents Providing Myeloprotection.mp4\u003c\/li\u003e\n\u003cli\u003eImmunotherapy in Breast Cancer Now \u0026amp; The Future.mp4\u003c\/li\u003e\n\u003cli\u003eImmunotherapy in NSCLC First Line for Advanced Disease.mp4\u003c\/li\u003e\n\u003cli\u003eKidney \u0026amp; Bladder Cancer Targeted, Immuno \u0026amp; Other Strategies.mp4\u003c\/li\u003e\n\u003cli\u003eManagement of Malignant Hypercalcemia, Bone Metastases \u0026amp; Standard Precautions to Decrease Adverse Events.mp4\u003c\/li\u003e\n\u003cli\u003eMyelodysplasia De Novo and Acquired- What To Do.mp4\u003c\/li\u003e\n\u003cli\u003eNew Platforms and Developments of Immunotherapy Biomarkers Beyond PD-L1 in Tissue.mp4\u003c\/li\u003e\n\u003cli\u003eNovel Advances in Multiple Myeloma as Front-Line Therapy.mp4\u003c\/li\u003e\n\u003cli\u003eProstate Cancer Diagnostic and Therapeutic Updates.mp4\u003c\/li\u003e\n\u003cli\u003eSmall Cell Lung Cancer.mp4\u003c\/li\u003e\n\u003cli\u003eTargeted Therapy and Immunotherapy for Soft Tissue Tissue Sarcomas.mp4\u003c\/li\u003e\n\u003cli\u003eTriple Negative Breast Cancer Optimal Strategies.mp4\u003c\/li\u003e\n\u003cli\u003eUpdates in Waldenstroms Macroglobulinemia.mp4\u003c\/li\u003e\n\u003cli\u003eWhat To Do When Patients Getting Immunotherapy Do Not Respond to Steroids (Hepatitis, Colitis, Pneumonitis, and Others).mp4\u003c\/li\u003e\n\u003c\/ul\u003e","brand":"meducours","offers":[{"title":"Default Title","offer_id":42954390405218,"sku":"MED-AMB02492","price":50.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0662\/9549\/6802\/files\/MEC-20th-Annual-Miami-Cancer-Meeting-2024.jpg?v=1779375185","url":"https:\/\/meducourse.com\/products\/mec-20th-annual-miami-cancer-meeting-2024","provider":"Meducourse","version":"1.0","type":"link"}